RMA
FLNA

Roffman Miller Associates’s Filana Therapeutics FLNA Stock Holding History

Roffman Miller Associates’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,000
Closed -$24.5K – 144
2023
Q2 		$24.5K Buy
+1,000
New +$24.1K ﹤0.01% 93

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Roffman Miller Associates's FLNA Position: Q3 2023 in Review

Roffman Miller Associates sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 1,000 shares — an estimated $24.5K sold.

Roffman Miller Associates first reported a position in FLNA in Q2 2023 and held it in 1 quarter. The position peaked at $24.5K in Q2 2023. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

  • Roffman Miller Associates reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Roffman Miller Associates sold 1,000 Filana Therapeutics shares in Q3 2023, an estimated $24.5K.
  • Roffman Miller Associates first reported a position in Filana Therapeutics in Q2 2023 and held it in 1 quarter.
  • Roffman Miller Associates's Filana Therapeutics position peaked at $24.5K in Q2 2023.
  • 140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on Roffman Miller Associates's 13F filing for Q3 2023, filed 9 Nov 2023.